Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study
2023 · The Lancet Respiratory Medicine · 137 citations
https://doi.org/10.1016/s2213-2600(23)00338-7
K
Kuo-Hsuan Hsu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
90
Papers
2.2K
Citations
26
h-index
52
i10-index
Kuo-Hsuan Hsu is an academic researcher from Taichung Veterans General Hospital. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Lung Cancer Diagnosis and Treatment. The author has an h-index of 26, co-authored 77 publications.
ORCID: 0000-0002-8187-904XPapers by this author
worksUrine neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute canine kidney injury
2012 · BMC Veterinary Research · 79 citations
https://doi.org/10.1186/1746-6148-8-248
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
2020 · Scientific Reports · 39 citations
https://doi.org/10.1038/s41598-020-78152-1
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients
2022 · Scientific Reports · 39 citations
https://doi.org/10.1038/s41598-022-13102-7
The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
2021 · Scientific Reports · 19 citations
https://doi.org/10.1038/s41598-021-91657-7
<i>EGFR</i>-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma
2016 · Oncotarget · 15 citations
https://doi.org/10.18632/oncotarget.7029
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat